187 related articles for article (PubMed ID: 19756602)
1. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
Liu J; Li X; Cheng YN; Cui SX; Chen MH; Xu WF; Tian ZG; Makuuchi M; Tang W; Qu XJ
Eur J Pharmacol; 2007 Nov; 574(1):1-7. PubMed ID: 17904544
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil.
Liu J; Xu WF; Cui SX; Zhou Y; Yuan YX; Chen MH; Wang RH; Gai RY; Makuuchi M; Tang W; Qu XJ
World J Gastroenterol; 2006 Nov; 12(42):6766-70. PubMed ID: 17106923
[TBL] [Abstract][Full Text] [Related]
4. The in vitro anti-tumor efficacy and the pharmacokinetics of N3-o-toluyl-fluorouracil loaded nanosuspension (TFu-LNS).
Li M; Zhang J; Feng L; Zhang L; Zhang N
J Biomed Nanotechnol; 2013 May; 9(5):801-10. PubMed ID: 23802409
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice.
Zhang J; Li M; Liu Z; Wang L; Liu Y; Zhang N
Int J Nanomedicine; 2014; 9():2741-51. PubMed ID: 24920908
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.
Sun W; Zhang N; Li A; Zou W; Xu W
Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370
[TBL] [Abstract][Full Text] [Related]
7. Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
Liu Y; Bi T; Dai W; Wang G; Qian L; Gao Q; Shen G
Tumour Biol; 2016 Jun; 37(6):7589-97. PubMed ID: 26687645
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
Hu Z; Lv G; Li Y; Li E; Li H; Zhou Q; Yang B; Cao W
J Exp Clin Cancer Res; 2016 Apr; 35():71. PubMed ID: 27102814
[TBL] [Abstract][Full Text] [Related]
9. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
[TBL] [Abstract][Full Text] [Related]
10. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
[TBL] [Abstract][Full Text] [Related]
11. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
[TBL] [Abstract][Full Text] [Related]
12. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
13. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
14. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
Huang C; Li NM; Gao P; Yang S; Ning Q; Huang W; Li ZP; Ye PJ; Xiang L; He DX; Tan XW; Yu CY
Drug Deliv; 2017 Nov; 24(1):459-466. PubMed ID: 28219253
[TBL] [Abstract][Full Text] [Related]
16. PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
Katsura Y; Wada H; Murakami M; Akita H; Hama N; Kawamoto K; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S517-26. PubMed ID: 23508585
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
[TBL] [Abstract][Full Text] [Related]
18. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
[TBL] [Abstract][Full Text] [Related]
19. Release mechanism studies on TFu nanoparticles-in-microparticles system.
Sun W; Zhang N; Li X
Colloids Surf B Biointerfaces; 2012 Jun; 95():115-20. PubMed ID: 22424827
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.
Zheng JF; Wang HD
World J Gastroenterol; 2005 Jul; 11(25):3944-7. PubMed ID: 15991299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
